Nasdaq Rare Disease Bio, Venture Fund Sells Shares Worth 300 Billion Won in a Week

Dyne Therapeutics, Inc. (Nasdaq: DYN) executed consecutive open‐market sales of over 1.1 million shares of its common stock between April 20–22 and April 23–27 through Atlas Venture–affiliated funds, pursuant to a Rule 10b5-1 trading plan adopted on March 19. According to the first Form 4 filing, Jason P. Rhodes, via four funds, sold approximately 739,000 shares at prices ranging from $19.50 to $20.10 per share, netting about $14.7–$14.8 million (approximately KRW 200 billion). In a second filing, an additional 401,000 shares were sold at $18.20–$19.20 per share, generating roughly $7.4 million (around KRW 100 billion). After these sales, the Atlas-affiliated funds still hold several million shares of Dyne’s stock. The filings also state that Mr. Rhodes disclaims any beneficial ownership beyond his economic interest in the funds.

On April 27, the company announced it will present nonclinical data at the 2026 annual meeting of the American Society of Gene & Cell Therapy (ASGCT), demonstrating that its FORCE platform crosses the blood–brain barrier and robustly reduces MAPT RNA in the central nervous system of nonhuman primate models (). Additionally, on April 23, under Nasdaq Listing Rule 5635(c)(4), Dyne granted stock options and restricted stock units to 18 new employees as inducement awards to support its ongoing expansion ().

Headquartered in Waltham, Massachusetts, Dyne Therapeutics is a clinical‐stage biotechnology company developing treatments for genetic neuromuscular disorders such as Duchenne muscular dystrophy and type 1 spinal muscular atrophy. Its common stock trades on Nasdaq under the ticker DYN (). The company plans to release additional clinical data on its lead candidates, z-basivarsen and z-rostudirsen, and is preparing to advance into Phase 3 trials as it transitions toward commercialization in the rare disease space.